Abstract 2006 Assessing Alterations in Hepatic Oxidation In MASLD/MASH via Preclinical Deuterium Metabolic MRI

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its advanced form, metabolic dysfunction-associated steatohepatitis (MASH) are a rising health risk in the US. MASLD/MASH patients are at an increased risk of liver fibrosis, cirrhosis, and ultimately liver failure. Due to the increased prevalence of obesity in the United States, MASH is anticipated to become the primary driver of liver transplantations by 2030. While previous studies have shown that hepatic oxidative metabolism in MASLD can be correlated to disease progression, the metabolic underpinnings of the disease remain elusive.